PT680325E - Sistema terapeutico transdermico com galantamina como componente activo - Google Patents
Sistema terapeutico transdermico com galantamina como componente activoInfo
- Publication number
- PT680325E PT680325E PT94905024T PT94905024T PT680325E PT 680325 E PT680325 E PT 680325E PT 94905024 T PT94905024 T PT 94905024T PT 94905024 T PT94905024 T PT 94905024T PT 680325 E PT680325 E PT 680325E
- Authority
- PT
- Portugal
- Prior art keywords
- pct
- therapeutic system
- galantamine
- active component
- sec
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4301783A DE4301783C1 (de) | 1993-01-23 | 1993-01-23 | Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT680325E true PT680325E (pt) | 2002-09-30 |
Family
ID=6478781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT94905024T PT680325E (pt) | 1993-01-23 | 1994-01-10 | Sistema terapeutico transdermico com galantamina como componente activo |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5700480A (pt) |
| EP (1) | EP0680325B1 (pt) |
| JP (1) | JPH08505632A (pt) |
| KR (1) | KR100300477B1 (pt) |
| AT (1) | ATE216240T1 (pt) |
| AU (1) | AU679032B2 (pt) |
| CA (1) | CA2153572C (pt) |
| CZ (1) | CZ287053B6 (pt) |
| DE (2) | DE4301783C1 (pt) |
| DK (1) | DK0680325T3 (pt) |
| ES (1) | ES2176234T3 (pt) |
| FI (1) | FI113744B (pt) |
| HR (1) | HRP940028B1 (pt) |
| HU (1) | HU221165B1 (pt) |
| IL (1) | IL108235A (pt) |
| MY (1) | MY109926A (pt) |
| NO (1) | NO307497B1 (pt) |
| NZ (1) | NZ259857A (pt) |
| PH (1) | PH31473A (pt) |
| PL (1) | PL175083B1 (pt) |
| PT (1) | PT680325E (pt) |
| SI (1) | SI9400024A (pt) |
| SK (1) | SK281339B6 (pt) |
| WO (1) | WO1994016707A1 (pt) |
| YU (1) | YU48607B (pt) |
| ZA (1) | ZA94414B (pt) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4429791C2 (de) * | 1994-08-23 | 1997-04-24 | Lohmann Therapie Syst Lts | Medizinischer Haftkleber auf Basis von Polyacrylaten und dessen Verwendung |
| DE19509663A1 (de) | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
| AU732803B2 (en) * | 1996-01-17 | 2001-05-03 | National Starch And Chemical Investment Holding Corporation | Adhesives resistant to skin-penetration enhancers |
| AT402691B (de) * | 1996-01-26 | 1997-07-25 | Sanochemia Ltd | Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome |
| ATE322272T1 (de) * | 1996-07-15 | 2006-04-15 | Alza Corp | Neue formulierungen zur transdermale verabreichung von fluoxetin |
| US6512010B1 (en) | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
| DE19649534B4 (de) * | 1996-11-29 | 2004-05-06 | Lts Lohmann Therapie-Systeme Ag | Verpackung aus Verbundpackstoff zum Verpacken von wirkstoffhaltigen Pflastern |
| DE19653605C2 (de) * | 1996-12-20 | 2002-11-28 | Roehm Gmbh | Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems |
| US6203817B1 (en) | 1997-02-19 | 2001-03-20 | Alza Corporation | Reduction of skin reactions caused by transdermal drug delivery |
| US5968547A (en) * | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| US6193993B1 (en) | 1998-03-03 | 2001-02-27 | Eisai Co., Ltd. | Suppository containing an antidementia medicament |
| SI1140105T1 (en) * | 1998-12-24 | 2004-04-30 | Janssen Pharmaceutica N.V. | Controlled release galantamine composition |
| US6241998B1 (en) | 1999-02-02 | 2001-06-05 | Acutek International | Dermatological patch |
| DE19906977C1 (de) * | 1999-02-19 | 2000-06-15 | Lohmann Therapie Syst Lts | Desoxypeganin-TTS und seine Verwendung |
| EP1221315A4 (en) * | 1999-10-13 | 2007-12-12 | Senju Pharma Co | ADHESIVE OPHTHALMIC PREPARATIONS FOR PERCUTANEOUS SPREADING |
| MXPA02005667A (es) | 1999-12-10 | 2004-09-10 | Bonnie Davis | Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos. |
| KR101250021B1 (ko) * | 2000-05-26 | 2013-04-03 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 완화된 부작용을 갖는 신규 재조합 아데노바이러스 벡터 |
| FR2814368B1 (fr) * | 2000-09-26 | 2004-05-07 | Pf Medicament | Preparation pharmaceutique a base d'oxans |
| DE10141652B4 (de) * | 2001-08-24 | 2011-04-07 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung |
| DE10235556A1 (de) * | 2002-08-03 | 2004-02-19 | Hf Arzneimittelforschung Gmbh | Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums |
| US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
| CA2551946A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galantamine |
| WO2005065662A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
| AT500143A1 (de) * | 2004-04-22 | 2005-11-15 | Sanochemia Pharmazeutika Ag | Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung |
| EP1895995A2 (en) | 2005-05-13 | 2008-03-12 | Alza Corporation | Multilayer drug system for the delivery of galantamine |
| WO2007035941A2 (en) * | 2005-09-23 | 2007-03-29 | Alza Corporation | Transdermal galantamine delivery system |
| TWI389709B (zh) * | 2005-12-01 | 2013-03-21 | Novartis Ag | 經皮治療系統 |
| DE102008059054A1 (de) | 2008-11-26 | 2010-05-27 | Otto Bock Pur Life Science Gmbh | Polyurethanpflaster für die transdermale Applikation von Wirkstoffen und Verfahren zu dessen Herstellung |
| US9844515B2 (en) | 2010-11-17 | 2017-12-19 | Hexal Ag | Transdermal therapeutic system comprising buprenorphine |
| KR101317158B1 (ko) | 2011-02-18 | 2013-10-15 | 조선대학교산학협력단 | 갈란타민 또는 그의 염을 함유하는 경피흡수제제 |
| EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| JP6285820B2 (ja) * | 2014-08-07 | 2018-02-28 | 久光製薬株式会社 | ガランタミン含有経皮吸収製剤 |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| BR112018070199A2 (pt) | 2016-04-01 | 2019-01-29 | Therapeuticsmd Inc | composição farmacêutica de hormônio esteroide |
| US20180008612A1 (en) * | 2016-07-11 | 2018-01-11 | Taho Pharmaceuticals Ltd. | Transdermal delivery system containing galantamine or salts thereof |
| CA3155267A1 (en) | 2019-11-06 | 2021-05-14 | Thomas Hnat | Topical formulations of cyclooxygenase inhibitors and their use |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU560710B2 (en) * | 1983-04-27 | 1987-04-16 | Lohmann Gmbh & Co. Kg. | Pharmaceutical product |
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| DE3843239C1 (pt) * | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
| DE4010079A1 (de) * | 1990-03-29 | 1991-10-02 | Lohmann Therapie Syst Lts | Pharmazeutische formulierung zur behandlung des alkoholismus |
| WO1992020327A1 (en) * | 1991-05-14 | 1992-11-26 | Ernir Snorrason | Treatment of fatigue syndrome with cholinesterase inhibitors |
-
1993
- 1993-01-23 DE DE4301783A patent/DE4301783C1/de not_active Expired - Lifetime
- 1993-12-30 IL IL10823593A patent/IL108235A/en not_active IP Right Cessation
-
1994
- 1994-01-10 EP EP94905024A patent/EP0680325B1/de not_active Expired - Lifetime
- 1994-01-10 WO PCT/EP1994/000054 patent/WO1994016707A1/de active IP Right Grant
- 1994-01-10 KR KR1019950703008A patent/KR100300477B1/ko not_active IP Right Cessation
- 1994-01-10 AU AU58817/94A patent/AU679032B2/en not_active Ceased
- 1994-01-10 DE DE59410103T patent/DE59410103D1/de not_active Expired - Lifetime
- 1994-01-10 NZ NZ259857A patent/NZ259857A/en not_active IP Right Cessation
- 1994-01-10 SK SK889-95A patent/SK281339B6/sk not_active IP Right Cessation
- 1994-01-10 HU HU9501928A patent/HU221165B1/hu not_active IP Right Cessation
- 1994-01-10 DK DK94905024T patent/DK0680325T3/da active
- 1994-01-10 JP JP6516614A patent/JPH08505632A/ja active Pending
- 1994-01-10 PL PL94309603A patent/PL175083B1/pl not_active IP Right Cessation
- 1994-01-10 CA CA002153572A patent/CA2153572C/en not_active Expired - Fee Related
- 1994-01-10 ES ES94905024T patent/ES2176234T3/es not_active Expired - Lifetime
- 1994-01-10 AT AT94905024T patent/ATE216240T1/de active
- 1994-01-10 US US08/495,609 patent/US5700480A/en not_active Expired - Lifetime
- 1994-01-10 CZ CZ19951842A patent/CZ287053B6/cs not_active IP Right Cessation
- 1994-01-10 PT PT94905024T patent/PT680325E/pt unknown
- 1994-01-17 MY MYPI94000112A patent/MY109926A/en unknown
- 1994-01-19 PH PH47631A patent/PH31473A/en unknown
- 1994-01-20 HR HRP4301783.5A patent/HRP940028B1/xx not_active IP Right Cessation
- 1994-01-20 ZA ZA94414A patent/ZA94414B/xx unknown
- 1994-01-21 SI SI9400024A patent/SI9400024A/sl unknown
- 1994-01-21 YU YU2694A patent/YU48607B/sh unknown
-
1995
- 1995-07-21 NO NO952907A patent/NO307497B1/no not_active IP Right Cessation
- 1995-07-21 FI FI953533A patent/FI113744B/fi not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT680325E (pt) | Sistema terapeutico transdermico com galantamina como componente activo | |
| BR0109893A (pt) | Preparação farmacêutica de lerisetron na forma de um sistema terapêutico transdêrmico, uso da preparação, uso da substância ativa lerisetron e método para administrar a substância ativa lerisetron a um paciente | |
| AR003413A1 (es) | Parches medicinales para la administracion transdermica de risperidona con liberacion controlada a traves de la piel intacta durante un periodo de tiempo prolongado | |
| ES2105334T3 (es) | Sistema terapeutico percutaneo para la administracion de fisostigmina en la piel y el procedimiento para su obtencion. | |
| BRPI0011135B8 (pt) | sistema de ministração terapêutica transdérmica contendo agente neuroléptico |